Insider buying · SEC Form 4

Insider Buying — Oct 28, 2026

Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.

5insider buys
$91.9Mbought in total
5companies
1by CEOs, CFOs and other chiefs
LYCAlargest: $37.7M

Every qualifying buy, largest first

StockInsiderValueSharesAvg priceTypeFiled
LYCALycia Therapeutics, Inc.Bong Y. Koh / Venrock Healthcare Capital Partners III, L.P.10% Owner$37.7M2,045,440$18.41New stakeOct 27, 2026
Form 4 ↗
Includes 1,944,444 shares at $18.00 IPO allocation price ($35.0M) + 101,016 shares open-market at $25.68–$26.84 (~$2.65M). Stock now $26.11: +45.1% vs $18 IPO, -0.6% vs open-mkt avg ~$26.28. IPO closed Oct 26; conversion of Series C/D preferred to common also occurred that day.
MSMMSC Industrial Direct Co., Inc.Mitchell JacobsonDirector / 10% Owner$29.0M250,000$115.94AddedOct 27, 2026
Form 4 ↗
Wtd avg $115.94 (range $115.11–$116.72) across three tranches on Oct 23. No 10b5-1 plan cited. Also gifted 8,200 shares (code G). Stock now $118.38 (+2.1% since buy). Founder-family discretionary conviction buy.
LRNStride, Inc.Dylan G. Haggart / Fivespan Partners, LPDirector$12.2M154,196$78.98AddedOct 27, 2026
Form 4 ↗
Three tranches: 59,188 shares at $79.84 (Oct 23), 4,152 at $78.47 + 90,856 at $78.44 (Oct 26). Wtd avg ~$78.98. Stock now $79.21 (+0.3% since buy). Shares held indirectly through Fivespan Partners and Fivespan Partners Fund Ltd. Post-transaction holding: 1,898,911 shares.
SRRKScholar Rock Holding CorpSrinivas Akkaraju / Samsara BioCapitalDirector$12.0M289,470$41.45AddedOct 27, 2026
Form 4 ↗
Six tranches across Oct 23 and Oct 26. Price ranges: $40.77–$41.75 (Oct 23), $41.78–$41.85 (Oct 23 second lot), $41.15–$41.93 (Oct 26). Wtd avg ~$41.45. Stock now $42.49 (+2.5% since buy). Held via Samsara BioCapital LP and Samsara Opportunity Fund LP; Akkaraju is founder/MD of Samsara, a healthcare-focused VC.
AIOKAI OKTO Corp.Petros PanagiotidisChief Executive Officer / Director$1.06M130,000$8.15AddedOct 27, 2026
Form 4 ↗
Six tranches on Oct 23. Prices ranged $5.53–$13.36, wtd avg ~$8.15. Shares held via Pani Corp (indirect). Stock now $13.42 (+64.7% since buy). CEO aggressively accumulated during an intraday swing — appears to be well-timed.

AIThe day in insider buying

SEC Form 4 Insider Scan — October 28, 2026

Scanned the last 24 hours of EDGAR Form 4 filings. 5 qualifying buys (≥ $250K, transaction type P) totalling $91.9M.

Headline filings

  • LYCA — Venrock Healthcare Capital Partners III (10% Owner) bought 2,045,440 shares ≈ $37.7M (1,944,444 at $18.00 IPO price + 101,016 at $25.68–$26.84 market avg ~$26.28); now $26.11 (+45.1% vs $18 IPO price; -0.6% vs open-mkt avg). (filing)
  • MSM — Mitchell Jacobson (Director / 10% Owner) bought 250,000 shares ≈ $29.0M at $115.94 wtd avg; now $118.38 (+2.1% since buy). No 10b5-1 plan cited — discretionary conviction buy. (filing)
  • LRN — Dylan G. Haggart / Fivespan Partners (Director) bought 154,196 shares ≈ $12.2M at $78.98 wtd avg; now $79.21 (+0.3% since buy). (filing)
  • SRRK — Srinivas Akkaraju / Samsara BioCapital (Director) bought 289,470 shares ≈ $12.0M at $41.45 wtd avg (range $40.77–$41.93); now $42.49 (+2.5% since buy). (filing)
  • AIOK — Petros Panagiotidis (CEO / Director) bought 130,000 shares ≈ $1.1M at $8.15 wtd avg (range $5.53–$13.36); now $13.42 (+64.7% since buy). (filing)

Notes

LYCA — IPO Day Buy: Venrock's $35M purchase at the $18.00 IPO price is an offering allocation (IPO committed capital), not a secondary-market buy; their additional $2.65M in post-IPO open-market purchases at $25–$27 reflects continued conviction after the stock immediately popped. Lycia Therapeutics is a newly-public clinical-stage bispecific antibody company (EGFR × LGR5 and related targets). The VC is keeping risk-on despite having already converted ~$40M+ of preferred into common at IPO.

MSM — Founder-Family Conviction: Jacobson is a founder-family 10% owner making a very large discretionary open-market purchase (~250K shares, no 10b5-1 plan cited). MSC Industrial Direct is an industrial distributor with historically resilient cash flows — this signals deep value conviction during what may be sector softness.

LRN + SRRK — Simultaneous Director Buys: Both filed Oct 27, with trade dates Oct 23–26. Stride is a K-12 digital learning company; Scholar Rock is a muscle-disease biotech focused on TGF-β biology. Different sectors, but the back-to-back large director purchases in the same EDGAR window are worth noting as a cross-sector signal of insider optimism after any mid-week softness.

AIOK — CEO Timing: The CEO's $1.1M buy at ~$8.15 avg appears prescient — AIOK has surged to $13.42 (+64.7%) as of today's quote. The wide price range ($5.53–$13.36) across six tranches suggests aggressive accumulation through a volatile session.

Most-bought stocks, last 30 days

  • LEN $193M · 1 buyLennar Corporation
  • CRBG $114M · 9 buys, 2 insidersCorebridge Financial, Inc.
  • GPI $64.2M · 3 buys, 2 insidersGroup 1 Automotive Inc.
  • BORR $51.3M · 8 buysBorr Drilling Ltd
  • GME $50.7M · 4 buys, 2 insidersGameStop Corp.
  • LYCA $37.7M · 1 buyLycia Therapeutics, Inc.
  • ADRX $37.3M · 2 buys, 2 insidersADARx Pharmaceuticals, Inc.
  • MSM $29.0M · 1 buyMSC Industrial Direct Co., Inc.
  • BPRE $22.2M · 4 buysBluerock Private Real Estate Fund
  • QVCG $16.7M · 1 buyQVC Group, Inc.
  • AVR $16.6M · 4 buysAnteris Technologies Global Corp.
  • LRN $12.2M · 1 buyStride, Inc.
  • SRRK $12.0M · 1 buyScholar Rock Holding Corp
  • IAM $11.5M · 1 buyIambic Therapeutics, Inc.
  • COUR $11.4M · 1 buyCoursera, Inc.
  • PSUS $9.61M · 1 buyPershing Square USA, Ltd.
  • DOLE $8.55M · 1 buyDole plc
  • APLD $6.66M · 2 buys, 2 insidersApplied Digital Corp.
  • GPUS $5.00M · 1 buyHyperscale Data, Inc.
  • NYAX $4.61M · 1 buyNayax Ltd.

All scans

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.